Full Press Release Details
TELA Bio Announces Changes to its Board
MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc.
("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing
a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that it
has appointed Doug Evans, the President and Chief Executive Officer of Lungpacer Medical Inc., and Lisa Colleran, a principal of
LNC Advisors, LLC, to its board of directors effective April 20, 2020.
As part of this announcement, Doug Evans will also assume the
Chairman of the Board of Directors role from Kurt Azabarzin, who will continue to serve as an independent board member. Furthermore,
current board members Ashley Friedman, Matt Zuga, and Ron Ellis will be stepping down. Following these changes, TELA Bio's board
will be composed of seven directors, six of whom are independent.
"We are excited to have Doug and Lisa join our Board as
we continue our transition as a public company and focus on our efforts to drive commercial adoption of our OviTex and OviTex
PRS product lines," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Their collective
leadership experience and knowledge of the medical devices field make Doug and Lisa excellent additions to TELA Bio."
Koblish added: "I would also like to take this opportunity
to thank Ashley, Matt, and Ron for their service and long-standing commitment to TELA Bio. We greatly appreciate their impactful
contributions through our initial commercialization and during our successful initial public offering process."
served as the President and Chief Executive Officer of Lungpacer Medical Inc., a medical device company, since January 2014.
Before joining Lungpacer, Mr. Evans served as the Chief Operating Officer and a member of the board of directors of Kensey
Nash Corporation, a medical device company, from March 1995 to June 2013. Mr. Evans currently serves on the board
of directors of Intact Vascular, a medical device company. Mr. Evans holds a Master of Science degree in Electrical Engineering
and Photonics from the University of Pennsylvania, an M.B.A. from Pennsylvania State University Great Valley School of Graduate
Professional Studies, and a Bachelor of Science in Engineering Sciences from the Pennsylvania State University.
been the principal of LNC Advisors, LLC, a strategic consulting firm that specializes in assisting biotech, pharmaceutical, and
medical device companies since February 2014. From October 2018 to September 2019, Ms. Colleran served as the
Chief Executive Officer of Vivex Biomedical, Inc., and from January 2014 to October 2018, she served as Principal
of Mica Partners, a strategic consulting firm. Prior to founding LNC Advisors, Ms. Colleran served as chief executive officer
of LifeCell Corporation and a board member for Centaur Guernsey L.P. (a holding company of LifeCell Corporation) from January 2012
to April 2013. Ms. Colleran also served as the global president of LifeCell Corporation from May 2008 to January 2012.
Prior to assuming the role of global president, Ms. Colleran served as LifeCell's vice president of marketing and business
development from December 2002 until July 2004 and as senior vice president of commercial operations from July 2004
until May 2008. Prior to joining LifeCell, Ms. Colleran served as vice president and general manager of Renal Pharmaceuticals
for Baxter Healthcare Corporation from 2000 to 2002. She served in various other sales and marketing positions at Baxter, from
1983 to 2000. Ms. Colleran currently serves on the board of directors for Establishment Labs, an innovative breast implant
company, Ariste Medical, a medical device company, and Rockwell Medical, a specialty pharmaceutical company focused on renal failure.
Ms. Colleran holds an M.B.A. from Loyola University of Chicago and a B.S.N. degree from Molloy College.
About TELA Bio, Inc.
is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement
materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of
existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality,
data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially
Corporate Development and Investor Relations